Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 16;3(1):vdab011. doi: 10.1093/noajnl/vdab011

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Pre-operative cfDNA concentration is associated with survival irrespective of MGMT promoter status. Kaplan–Meier survival curves for progression-free survival (A) and overall survival (B) for 25 MGMT promoter methylation positive patients, and for progression-free survival (C) and overall survival (D) for 37 MGMT negative patients. Low vs. high plasma cfDNA designates patients below or above the median pre-operative cfDNA concentration of 25.2 ng/mL, respectively.